Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1991 Jan;63(1):15–16. doi: 10.1038/bjc.1991.6

LHRH analogues in breast cancer: clever, but do we need them?

I E Smith
PMCID: PMC1971625  PMID: 1989655

Full text

PDF
15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buchanan R. B., Blamey R. W., Durrant K. R., Howell A., Paterson A. G., Preece P. E., Smith D. C., Williams C. J., Wilson R. G. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986 Sep;4(9):1326–1330. doi: 10.1200/JCO.1986.4.9.1326. [DOI] [PubMed] [Google Scholar]
  2. Crighton I. L., Dowsett M., Lal A., Man A., Smith I. E. Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects. Br J Cancer. 1989 Oct;60(4):644–648. doi: 10.1038/bjc.1989.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dixon A. R., Robertson J. F., Jackson L., Nicholson R. I., Walker K. J., Blamey R. W. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br J Cancer. 1990 Nov;62(5):868–870. doi: 10.1038/bjc.1990.397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eidne K. A., Flanagan C. A., Millar R. P. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science. 1985 Sep 6;229(4717):989–991. doi: 10.1126/science.2992093. [DOI] [PubMed] [Google Scholar]
  5. Harris A. L., Carmichael J., Cantwell B. M., Dowsett M. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer. Br J Cancer. 1989 Jan;59(1):97–99. doi: 10.1038/bjc.1989.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Harvey H. A., Lipton A., Max D. T., Pearlman H. G., Diaz-Perches R., de la Garza J. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J Clin Oncol. 1985 Aug;3(8):1068–1072. doi: 10.1200/JCO.1985.3.8.1068. [DOI] [PubMed] [Google Scholar]
  7. Ingle J. N., Krook J. E., Green S. J., Kubista T. P., Everson L. K., Ahmann D. L., Chang M. N., Bisel H. F., Windschitl H. E., Twito D. I. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol. 1986 Feb;4(2):178–185. doi: 10.1200/JCO.1986.4.2.178. [DOI] [PubMed] [Google Scholar]
  8. Kaufmann M., Jonat W., Kleeberg U., Eiermann W., Jänicke F., Hilfrich J., Kreienberg R., Albrecht M., Weitzel H. K., Schmid H. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol. 1989 Aug;7(8):1113–1119. doi: 10.1200/JCO.1989.7.8.1113. [DOI] [PubMed] [Google Scholar]
  9. Klijn J. G. Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother. 1984;1(2):123–128. doi: 10.1007/BF02934984. [DOI] [PubMed] [Google Scholar]
  10. Miller W. R., Scott W. N., Morris R., Fraser H. M., Sharpe R. M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 1985 Jan 17;313(5999):231–233. doi: 10.1038/313231a0. [DOI] [PubMed] [Google Scholar]
  11. Nicholson R. I., Maynard P. V. Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer. 1979 Mar;39(3):268–273. doi: 10.1038/bjc.1979.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Plowman P. N., Nicholson R. I., Walker K. J. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer. 1986 Dec;54(6):903–909. doi: 10.1038/bjc.1986.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B., McKinna J. A. Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 1990;26(6):680–684. doi: 10.1016/0277-5379(90)90116-b. [DOI] [PubMed] [Google Scholar]
  14. Waxman J. H., Harland S. J., Coombes R. C., Wrigley P. F., Malpas J. S., Powles T., Lister T. A. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol. 1985;15(2):171–173. doi: 10.1007/BF00257531. [DOI] [PubMed] [Google Scholar]
  15. Williams M. R., Walker K. J., Turkes A., Blamey R. W., Nicholson R. I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer. 1986 May;53(5):629–636. doi: 10.1038/bjc.1986.106. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES